Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Omnipaque 350 mgI/mL iohexol 200mL solution for injection (parametric release) (NZ)
Section 19A approved medicine
(Approval lapsed) Omnipaque 350 mgI/mL iohexol 200mL solution for injection (parametric release) (NZ)
Section 19A approval holder
GE Healthcare Pty Ltd ABN: 32 001 408 402
Phone
1300 887 764
Approved until
Status
Expired
Medicines in short supply/unavailable
OMNIPAQUE 350 iohexol 15.1g/20mL injection vial AUST R: 39868
Indication(s)
Intravascular: OMNIPAQUE is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. In children, OMNIPAQUE is indicated for angiography and urography.
Oral/body cavities: OMNIPAQUE is indicated in adults for arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, and in adults, children and premature babies for studies of the gastrointestinal tract.
Intrathecal: OMNIPAQUE is indicated for lumbar, thoracic, cervical and total columnar myelography and in computerised tomography of the CNS in adults and children.